NRXS
$7.62+0.46 (+6.42%)
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Recent News
Neuraxis Inc (NRXS) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Operational Challenges
Neuraxis Inc (NRXS) reports a 27% revenue increase in Q4 2025, while navigating higher operating expenses and strategic expansions.
NeurAxis, Inc. Q4 2025 Earnings Call Summary
Moby summary of NeurAxis, Inc.'s Q4 2025 earnings call
Top Stock Reports for Meta, Bank of America & Procter & Gamble
Meta Platforms leads today's Zacks Research Daily as analysts highlight strong user growth, heavier AI investment and lingering concerns around monetization.
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.
The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis
Zacks highlights Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis, providing research insights on their growth prospects, market performance, and key risks for investors.